Eyegene amends 2026 H1 report to add treasury shares disclosure
Eyegene filed a corrected 2026 H1 semi-annual report dated Sept. 29 adding treasury shares disclosures, including 6,908 common shares held as of June 30 (0.01% of issued shares) and plans to finalize a cancellation plan in 2027 H1 under amended Korean Commercial Act transition rules.